Eli Lilly and Novo Nordisk just figured out that the human body has more than one hormone they can f*ck with to make you lose weight. Groundbreaking stuff. Took them this long to realize amylin exists.
GLP-1 drugs print money. Wegovy and Ozempic turned half of Los Angeles into walking skeletons who brag about their A1C levels at dinner parties. But apparently that wasn't enough. These companies need a second biological lever to pull because one wildly profitable mechanism of action is for quitters.
Amylin regulates blood sugar and appetite. It works differently than GLP-1. So the pitch here is simple: combine them both and you get people even skinnier. Double the hormones, double the revenue. This is the pharmaceutical equivalent of McDonald's asking if you want fries with that.
Retail traders will see this headline and immediately start Googling "what is amylin" while buying call options on LLY. They'll read one Seeking Alpha article written by a guy named QuantKing77 who has never taken a biology class. Then they'll lever up based on a hunch that "two drugs better than one drug" is a thesis. They won't notice that these amylin drugs are years away from approval. They won't care that clinical trials could fail. They'll just see the words "new wave of obesity drugs" and picture themselves retiring early.
The funniest part is that none of this matters for the stock price today. Lilly is already up 40% this year because GLP-1 drugs are a cultural phenomenon. Amylin could cure cancer and the chart would look exactly the same. But sure, let's pretend this headline changes anything.
By the time these amylin drugs hit the market, retail will have blown up their accounts on three other biotech plays they read about in a Reddit thread.
Photo by on Unsplash
Leave a Comment